

[P-aminosalicylate sodium](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.2. Antibacterials](#) [6.2.5. Antituberculosis medicines](#)

ATC codes: [J04AA01](#)

EMLc

Indication

Multi-drug resistant Mycobacterium tuberculosis ICD11 code: [ML32.00](#)

Medicine type

Chemical agent

List type

Core

Additional notes

Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.

Formulations

Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

EML status history

First added in 2023 ([TRS 1049](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[P-aminosalicylate sodium](#)

DrugBank

[P-aminosalicylate sodium \(Aminosalicylic Acid\)](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.